Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Acetylsalicylzuur Apotex Cardio · 1 trial · 1 indication
PK samples collected pre-dose and at 5mins, 10 mins, 20 mins, 30 mins, 40mins, 50 mins, 1hr 15 mins, 1.5hrs, 2 hrs, 2hr 30 mins, 3hrs, 3hr 30 mins, 4 hrs, 5 hrs, 6hrs, 8hrs,10 hrs, 12hrs post-dose.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Capsule ASA 81mg/esomeprazole 20mg |
| 2 | ACTIVE_COMPARATOR | ASA (Acetylsalicylzuur Apotex cardio 80 mg) Tablet 80 mg |
| Name | Type | Description |
|---|---|---|
| Capsule ASA 81mg/esomeprazole 20mg | DRUG | Multiple doses administered on Day 1 to 5 |
| Acetylsalicylzuur Apotex Cardio | DRUG | Multiple doses administered on Day 1 to 5 |
Inclusion Criteria: * Healthy male and female subjects aged 20 to 50 years inclusive. * Have a body body mass index (BMI) of 18.0 to 30.0 kg/m2 inclusive and weigh 50.0 to 100.0 kg inclusive. * Females must be of non-childbearing potential or be of childbearing potential but have a negative serum h...
Acetylsalicylzuur Apotex Cardio is a small molecule drug candidate developed by AstraZeneca PLC. It has been studied in a Phase 1 clinical trial involving healthy adult volunteers. The specific therapeutic indications for this asset have not been publicly disclosed.
Acetylsalicylzuur Apotex Cardio is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor associated with the clinical development of this small molecule asset.
Acetylsalicylzuur Apotex Cardio is in Phase 1 clinical development. It is an investigational drug candidate and has completed one Phase 1 trial. No Phase 2 or later-stage trials for this asset have been recorded.
Acetylsalicylzuur Apotex Cardio has been evaluated in one completed Phase 1 trial, NCT01448031, titled A Healthy Female and Male Volunteers Aspirin Study. The trial enrolled 54 healthy volunteers in the United Kingdom, used an active-controlled randomized design, and included participants aged 20 years and older.
Acetylsalicylzuur Apotex Cardio is an investigational drug candidate in Phase 1 clinical development and is not approved for marketing. Its only recorded trial, NCT01448031, has completed, and no active trials for this asset are currently listed.